Article
CD122-Selective IL2 Complexes Reduce Immunosuppression, Promote Treg Fragility, and Sensitize Tumor Response to PD-L1 Blockade.
Cancer research - 15 Nov 2020
Drerup Justin M, Deng Yilun, Pandeswara Sri Lakshmi, Padrón Álvaro S, Reyes Ryan M, Zhang Xinyue, Mendez Jenny, Liu Aijie, Clark Curtis A, Chen Wanjiao, Conejo-Garcia José R, Hurez Vincent, Gupta Harshita, Curiel Tyler J
Abstract excerpt
The IL2 receptor (IL2R) is an attractive cancer immunotherapy target that controls immunosuppressive T regulatory cells (Treg) and antitumor T cells. Here we used IL2Rβ-selective IL2/anti-IL2 complexes (IL2c) to stimulate effector T cells preferentially in the orthotopic mouse ID8agg ovarian cancer model. Despite strong tumor rejection, IL2c unexpectedly lowered the tumor microenvironmental CD8+/Treg ratio. IL2c...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.